1-18 of 18
Nicholas C. Turner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception

Arielle J. Medford, Beverly Moy, Laura M. Spring, Sara A. Hurvitz, Nicholas C. Turner, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF9.
https://doi.org/10.1158/1078-0432.CCR-23-0757
Published: 01 September 2023
View article titled, Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception
Open the PDF for Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception in another window
Journal Articles

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, Claire Swift, Begoña Bermejo, Jesus Herranz, Mireia Margeli Vila, Antonio Antón, Zsuzsanna Kahan, Tibor Csöszi, Yuan Liu, Daniel Fernandez-Garcia, Isaac Garcia-Murillas, Michael Hubank, Nicholas C. Turner, Miguel Martín
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF12.
https://doi.org/10.1158/1078-0432.CCR-23-0956
Published: 30 August 2023
View article titled, Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Open the PDF for Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3433–3442.
https://doi.org/10.1158/1078-0432.CCR-22-0305
Published: 15 August 2022
View article titled, Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Open the PDF for Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study in another window
Includes: Supplementary data
Journal Articles

Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis

Amanda Fitzpatrick, Marjan Iravani, Adam Mills, Lucy Childs, Thanussuyah Alaguthurai, Angela Clifford, Isaac Garcia-Murillas, Steven Van Laere, Luc Dirix, Mark Harries, Alicia Okines, Nicholas C. Turner, Syed Haider, Andrew N.J. Tutt, Clare M. Isacke
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1180–1191.
https://doi.org/10.1158/1078-0432.CCR-21-3017
Published: 15 March 2022
View article titled, Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis
Open the PDF for Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis in another window
Includes: Supplementary data
Journal Articles

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Nicholas C. Turner, Judith Balmaña, Coralie Poncet, Theodora Goulioti, Konstantinos Tryfonidis, Aafke H. Honkoop, Gabriele Zoppoli, Evangelia Razis, Oskar T. Johannsson, Marco Colleoni, Andrew N. Tutt, William Audeh, Michail Ignatiadis, Audrey Mailliez, Olivier Trédan, Antonino Musolino, Peter Vuylsteke, Maria Jose Juan-Fita, Iain R.J. Macpherson, Bella Kaufman, Luis Manso, Lori J. Goldstein, Susan L. Ellard, István Láng, Kai Yu Jen, Virginie Adam, Saskia Litière, John Erban, David A. Cameron
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5482–5491.
https://doi.org/10.1158/1078-0432.CCR-21-0310
Published: 15 October 2021
View article titled, Niraparib for Advanced Breast Cancer with Germline <em>BRCA1</em> and <em>BRCA2</em> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
Open the PDF for Niraparib for Advanced Breast Cancer with Germline <em>BRCA1</em> and <em>BRCA2</em> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study in another window
Includes: Supplementary data
Journal Articles

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac Garcia-Murillas, Aman U. Budzar, John F.R. Robertson, William Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen R.D. Johnston, Stephen K. Chia
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (19): 5172–5177.
https://doi.org/10.1158/1078-0432.CCR-20-0224
Published: 01 October 2020
View article titled, <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Open the PDF for <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials in another window
Includes: Supplementary data
Journal Articles

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H. Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S. Hirst, Alan Barnicle, Elza C. de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B. Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C. Turner, Cristina Saura, Barry R. Davies, Mafalda Oliveira, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3720–3731.
https://doi.org/10.1158/1078-0432.CCR-19-3324
Published: 15 July 2020
View article titled, Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Open the PDF for Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts in another window
Includes: Supplementary data
Journal Articles

Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance

Alex Pearson, Paula Proszek, Javier Pascual, Charlotte Fribbens, Monee K. Shamsher, Belinda Kingston, Ben O'Leary, Maria T. Herrera-Abreu, Rosalind J. Cutts, Isaac Garcia-Murillas, Hannah Bye, Brian A. Walker, David Gonzalez De Castro, Lina Yuan, Sabri Jamal, Mike Hubank, Elena Lopez-Knowles, Eugene F. Schuster, Mitch Dowsett, Peter Osin, Ashutosh Nerurkar, Marina Parton, Alicia F.C. Okines, Stephen R.D. Johnston, Alistair Ring, Nicholas C. Turner
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (3): 608–622.
https://doi.org/10.1158/1078-0432.CCR-18-4044
Published: 03 February 2020
View article titled, Inactivating <em>NF1</em> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Open the PDF for Inactivating <em>NF1</em> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance in another window
Includes: Supplementary data
Journal Articles

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Rina Hui, Alex Pearson, Javier Cortes, Christine Campbell, Camille Poirot, Hatem A. Azim, Jr, Debora Fumagalli, Matteo Lambertini, Fergus Daly, Amal Arahmani, José Perez-Garcia, Philippe Aftimos, Philippe L. Bedard, Laura Xuereb, Elsemieke D. Scheepers, Malou Vicente, Theodora Goulioti, Sibylle Loibl, Sherene Loi, Marie-Jeanne Pierrat, Nicholas C. Turner, Fabrice Andre, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 354–363.
https://doi.org/10.1158/1078-0432.CCR-19-1164
Published: 15 January 2020
View article titled, Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Open the PDF for Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study in another window
Includes: Supplementary data
Journal Articles

Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors

Maria Coakley, Isaac Garcia-Murillas, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6026–6034.
https://doi.org/10.1158/1078-0432.CCR-19-0152
Published: 15 October 2019
View article titled, Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors
Open the PDF for Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors in another window
Journal Articles

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmaña, Peter A. Fasching, Sara A. Hurvitz, Andrew M. Wardley, Colombe Chappey, Alison L. Hannah, Mark E. Robson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (9): 2717–2724.
https://doi.org/10.1158/1078-0432.CCR-18-1891
Published: 01 May 2019
View article titled, A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <em>BRCA1/2</em> Mutations (ABRAZO)
Open the PDF for A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <em>BRCA1/2</em> Mutations (ABRAZO) in another window
Includes: Supplementary data
Journal Articles

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, Lei Tian, Jane L. Meisel, Isaac García-Murillas, Charlotte Fribbens, Ros Cutts, Luciano G. Martelotto, Charlotte K.Y. Ng, Raymond S. Lim, Pier Selenica, Salvatore Piscuoglio, Carol Aghajanian, Larry Norton, Rajmohan Murali, David M. Hyman, Laetitia Borsu, Maria E. Arcila, Jason Konner, Jorge S. Reis-Filho, Roger A. Greenberg, Mark E. Robson, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (21): 6708–6720.
https://doi.org/10.1158/1078-0432.CCR-17-0544
Published: 31 October 2017
View article titled, Diverse <em>BRCA1</em> and <em>BRCA2</em> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Open the PDF for Diverse <em>BRCA1</em> and <em>BRCA2</em> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer

Uzma S. Asghar, Alexis R. Barr, Ros Cutts, Matthew Beaney, Irina Babina, Deepak Sampath, Jennifer Giltnane, Jennifer Arca Lacap, Lisa Crocker, Amy Young, Alex Pearson, Maria Teresa Herrera-Abreu, Chris Bakal, Nicholas C. Turner
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (18): 5561–5572.
https://doi.org/10.1158/1078-0432.CCR-17-0369
Published: 14 September 2017
View article titled, Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Open the PDF for Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Tackling the Diversity of Triple-Negative Breast Cancer

Nicholas C. Turner, Jorge S. Reis-Filho
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (23): 6380–6388.
https://doi.org/10.1158/1078-0432.CCR-13-0915
Published: 01 December 2013
View article titled, Tackling the Diversity of Triple-Negative Breast Cancer
Open the PDF for Tackling the Diversity of Triple-Negative Breast Cancer in another window
Journal Articles

Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR

Heidrun Gevensleben, Isaac Garcia-Murillas, Monika K. Graeser, Gaia Schiavon, Peter Osin, Marina Parton, Ian E. Smith, Alan Ashworth, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (12): 3276–3284.
https://doi.org/10.1158/1078-0432.CCR-12-3768
Published: 13 June 2013
View article titled, Noninvasive Detection of <em>HER2</em> Amplification with Plasma DNA Digital PCR
Open the PDF for Noninvasive Detection of <em>HER2</em> Amplification with Plasma DNA Digital PCR in another window
Includes: Supplementary data
Journal Articles

FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo

Rachel Sharpe, Alex Pearson, Maria T. Herrera-Abreu, Damian Johnson, Alan Mackay, Jonathan C. Welti, Rachael Natrajan, Andrew R. Reynolds, Jorge S. Reis-Filho, Alan Ashworth, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (16): 5275–5286.
https://doi.org/10.1158/1078-0432.CCR-10-2727
Published: 14 August 2011
View article titled, FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nicholas Orr, Marina Parton, Ian E. Smith, Jorge S. Reis-Filho, Mitch Dowsett, Alan Ashworth, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 6159–6168.
https://doi.org/10.1158/1078-0432.CCR-10-1027
Published: 16 December 2010
View article titled, A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Open the PDF for A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer in another window
Includes: Supplementary data
Journal Articles

FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas

Jorge Sergio Reis-Filho, Pete T. Simpson, Nicholas C. Turner, Maryou Ballo Lambros, Chris Jones, Alan Mackay, Anita Grigoriadis, David Sarrio, Kay Savage, Tim Dexter, Marjan Iravani, Kerry Fenwick, Barbara Weber, David Hardisson, Fernando Carlos Schmitt, Jose Palacios, Sunil R. Lakhani, Alan Ashworth
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (22): 6652–6662.
https://doi.org/10.1158/1078-0432.CCR-06-1164
Published: 22 November 2006
View article titled, <em>FGFR1</em> Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas
Open the PDF for <em>FGFR1</em> Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas in another window
Includes: Supplementary data